Detection of JAK2 V617F mutation increases the diagnosis of myeloproliferative neoplasms
- Authors:
- Shu‑Peng Zhang
- Hui Li
- Ren‑Sheng Lai
View Affiliations
Affiliations: Department of Pathology, The Affiliated Hospital of Nanjing University of Traditional Chinese Medicine, Nanjing, Jiangsu 210029, P.R. China
- Published online on: December 12, 2014 https://doi.org/10.3892/ol.2014.2801
-
Pages:
735-738
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Abstract
The Janus kinase (JAK)2 gene, which is located on chromosome 9p24, is involved in the signaling transduction pathways of the hematopoietic and immune system. Mutations in the JAK2 gene have served as disease markers for myeloproliferative neoplasms (MPNs). The aim of the present study was to investigate the occurrence of the JAK2 gene mutation in 140 clinical samples, and to evaluate its clinical significance in MPNs and other hematological diseases. Genomic DNA was extracted from the peripheral blood leukocytes or bone marrow karyocytes of 140 clinical samples, which included 130 patients with various types of hematological disease and 10 control patients. In addition, exons 12 and 14 of the JAK2 gene were analyzed by direct sequencing and the mutation rates of various MPN subtypes were evaluated. Of the 140 samples, exons 12 and 14 were tested in 74 samples, however, exon 14 only was tested in 66 samples. No mutations were identified in exon 12. The V617F mutation rate in polycythemia vera was 82.1% (23/28), and the mutation rates in essential thrombocythemia histiocytosis, primary myelofibrosis and other MPNs were 53.1% (17/32), 40.0% (4/10) and 60.0% (6/10), respectively. Therefore, the total mutation rate of the JAK2 gene in MPN was 62.5% (50/80). For non‑MPN hematological diseases, four V617F mutations were detected in samples of leukocytosis of unknown origin (4/12), however, no JAK2 V617F mutations were identified in the 10 controls. Therefore, JAK2 V617F mutations may present a novel marker for diagnosis of MPNs. Furthermore, the direct sequencing method appeared to be satisfactory for the clinical gene testing of hematological samples.
View References
|
1
|
Tao P, Jinchang W, et al: JAK2 gene
mutation and MPN. China Medical Abstracts (Internal Medicine).
27:305–308. 2006.
|
|
2
|
Vardiman JW, Thiele J, Arber DA, et al:
The 2008 revision of the World Health Organiszation (WHO)
classification of myeloid neoplasms and acute leukemia: rationale
and important changes. Blood. 114:937–951. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kralovics R, Passamonti F, Buser AS, et
al: A gain-of-function mutation of JAK2 in myeloproliferative
disorders. N Engl J Med. 352:1779–1790. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Levine RL, Wadleigh M, Cools J, et al:
Activating mutation in the tyrosine kinase JAK2 in polycythemia
vera, essential thrombocythemia and myeloid metaplasia with
myelofibrosis. Cancer Cell. 7:387–397. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
James C, Ugo V, Le Couédic JP, et al: A
unique clonal JAK2 mutation leading to constitutive signaling
causes polycythaemia vera. Nature. 434:1144–1148. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Baxter EJ, Scottl M, Campbell PJ, et al;
Cancer Genome Project. Acquired mutation of the tyrosine kinase
JAK2 in human myeloproliferative disorders. Lancet. 365:1054–1061.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Scott LM, Tong W, Levine RL, et al: JAK2
exon 12 mutations in polycythemia vera and idiopathic
erythrocytosis. N Engl J Med. 356:459–468. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Levine RL, Belisle C, Wadleigh M, et al:
X-inactivation-based clonality analysis and quantitative JAK2V617F
assessment reveal a strong association between clonality and
JAK2V617F in PV but not ET/MMM, and identifies a subset of
JAK2V617F-negative ET and MMM patients with clonal hematopoiesis.
Blood. 107:4139–4141. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhao R, Xing S, Li Z, et al:
Identification of an acquired JAK2 mutation in polycythemia vera. J
Biol Chem. 280:22788–22792. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Vainchenker W and Constantinescu SN: A
unique activating mutation in JAK2 (V617F) is at the origin of
polycythemia vera and allows a new classification of
myeloproliferative diseases. Hematology Am Soc Hematol Educ
Program. 1:195–200. 2005. View Article : Google Scholar
|
|
11
|
Yeh YM, Chen YL, Cheng HY, et al: High
percentage of JAK2 exon 12 mutation in Asian patients with
polycythemia vera. Am J Clin Pathol. 134:266–270. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Schmitt-Graeff AH, Teo SS, Olschewski M,
et al: JAK2V617F mutation status identifies subtypes of refractory
anemia with ringed sideroblasts associated with marked
thrombocytosis. Haematologica. 93:34–40. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Panani AD: Janus kinase 2 mutations in
Philadelphia negative chronic myeloproliferative disorders:
clinical implications. Cancer Letters. 284:7–14. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Olsen RJ, Dunphy CH, O’Malley DP, et al:
The implication of identifying JAK2 (V617F) in myeloproliferative
neoplasms and myelodysplastic syndromes with bone marrow fibrosis.
J Hematop. 1:111–117. 2008. View Article : Google Scholar
|
|
15
|
Pardanania A: JAK2 inhibitor therapy in
myeloproliferative disorders: rationale, preclinical studies and
ongoing clinical trials. Leukemia. 22:23–30. 2008. View Article : Google Scholar
|
